Information about Fruzaqla (Fruquintinib)
Fruzaqla (Fruquintinib) is an oral medication used primarily for the treatment of advanced or metastatic colorectal cancer (CRC) and other solid tumors. It is a vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor. Fruquintinib specifically targets and inhibits the VEGF receptor 1, 2, and 3, which are involved in the growth of blood vessels (angiogenesis) that supply tumors with nutrients and oxygen. By inhibiting these pathways, Fruquintinib helps to starve tumors of the blood supply they need to grow and spread.
Fruzaqla is developed and approved in various regions, including China and other countries, for patients who have previously been treated with other therapies.
Primary Indications for Fruzaqla (Fruquintinib)
- Fruzaqla is indicated for the treatment of metastatic colorectal cancer, specifically for patients who have previously received chemotherapy and other treatments, such as fluoropyrimidine-based regimens, oxaliplatin, or irinotecan-based therapies.
- Though the primary indication is for CRC, Fruquintinib is also being investigated and used in clinical settings for other solid tumors, particularly when other lines of treatment have been exhausted.
Key Ingredient
Key Benefits
- By targeting the VEGF receptors, Fruzaqla prevents new blood vessels from forming, which helps cut off the nutrient supply to tumors, thus reducing tumor growth.
- Fruquintinib is beneficial for patients with metastatic colorectal cancer who have failed or become resistant to prior treatments like chemotherapy and biological agents.
- In clinical trials, Fruzaqla has demonstrated improvements in progression-free survival (PFS) for patients with advanced colorectal cancer.
- Fruzaqla is administered as an oral capsule, offering convenience compared to intravenous treatments.
- As a targeted therapy, Fruquintinib specifically affects the pathways involved in cancer cell growth and blood vessel formation, potentially causing fewer side effects compared to non-targeted therapies.
Direction of Use
- The recommended dosage of Fruzaqla (Fruquintinib) is typically 5 mg orally once daily for 3 weeks followed by a 1-week break (21-day cycle).
- Fruquintinib should be taken with or without food, swallowed whole with water. It is important to follow the prescribed cycle regimen closely.
- The length of treatment will depend on the patient’s response and the appearance of any side effects.
- Patients are monitored regularly for side effects like hypertension, liver function, and signs of bleeding, among others.
Safety Concerns
- One of the most common side effects of Fruzaqla is hypertension (high blood pressure). Patients should have their blood pressure monitored regularly, and antihypertensive treatment may be necessary.
- As a VEGF inhibitor, Fruquintinib can increase the risk of bleeding. Caution should be exercised in patients with a history of bleeding disorders or those undergoing surgery.
- There may be an increased risk of cardiovascular events, including heart failure and stroke, especially in patients with preexisting heart conditions. Close cardiovascular monitoring is required.
- Protein in the urine (proteinuria) may occur, and kidney function should be monitored during treatment.
- Liver enzyme abnormalities have been observed in clinical studies, so regular liver function tests are recommended.
- Some patients may experience nausea, diarrhea, or anorexia (loss of appetite).
- As with many cancer therapies, fatigue is a common side effect. It is important to manage energy levels and ensure proper nutrition.
Avoid Fruzaqla (Fruquintinib) If
- Fruzaqla should be avoided in patients with uncontrolled high blood pressure or in those who cannot manage their hypertension with medication.
- Due to the increased risk of bleeding, Fruquintinib should be avoided in patients with active bleeding or history of serious bleeding events.
- Fruzaqla is contraindicated in patients with severe hepatic impairment (e.g., cirrhosis), as it could exacerbate liver toxicity.
- Fruquintinib should be avoided during pregnancy and breastfeeding due to potential harm to the fetus or infant. Women of childbearing potential should use effective contraception during treatment.
- If a patient is allergic to Fruquintinib or any of its components, the medication should be avoided.
